A biotech company backed by Chinese conglomerate Fosun Group and private equity giant Warburg Pincus has begun one of the first mid-stage human trials of a drug discovered and designed by artificial intelligence.
由manbetx3.0 复星集团(Fosun Group)和私募股权巨头华平投资支持的一家生物技术公司，已经开始对一款由人工智能发现和设计的药物进行首批中期人体试验。
您已阅读7%（463字），剩余93%（5961字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。